XVIVO obtains financing from Vinnova for cancer research
Vinnova has decided to finance one of XVIVO Perfusion’s projects within In Vivo Lung Perfusion (IVLP) through the research and innovation program Research & Grow.
XVIVO Perfusion today has a leading international position in Ex Vivo Lung Perfusion (EVLP) with STEEN Solution™ and now sees an opportunity to use the established platform to expand within In Vivo Lung Perfusion (IVLP). The pre-study which Vinnova has decided to finance aims to evaluate the possibility of treating lung cancer by isolating the lung in situ and perfusing with chemoterapy. The method rinses isolated lungs in the body using STEEN Solution™, which acts as a carrier of cytotoxins. The hypothesis is that IVLP with STEEN Solution™ as a perfusate will result in fewer adverse effects.
"IVLP may prove to be revolutionary in the treatment of lung cancer. The pre-study is being performed together with one of the leading clinics in Europe and our aim is, if the pre-study is successful to create optimal conditions to carry out a clinical multicenter study," says Petra Apell, Regional Director at XVIVO Perfusion.
One problem with the treatment of certain forms of lung cancer is that there is a risk that the cytotoxins used to treat the cancer will destroy other organs in the body. By isolating the lung and only treating the lung with cytotoxins, adverse effects can be limited. As STEEN Solution™ enables perfusion of the lung, the solution can be used as a carrier of cytotoxins in the isolated lung.
"We are very pleased that Vinnova has decided to support this project financially. IVLP using STEEN Solution™ as a carrier of cancer drugs has good potential to reduce the adverse effects and may even increase survival rates for certain cancer patients", says Dr Magnus Nilsson, CEO of XVIVO Perfusion.
November 20, 2014
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson
CEO
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59, christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication on November 20, 2014 at 4:00 p.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
Tags: